AB-01 is under clinical development by Agastiya Biotech and currently in Phase I for Liver Cancer. According to GlobalData, Phase I drugs for Liver Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AB-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AB-001 is under development for the treatment of biliary tract cancer, stomach cancer, colon cancer, breast cancer, carcinoid tumor, gallbladder cancer, liver cancer, pancreatic cancer, lung cancer, acute lymphocytic leukemia and acute myeloid leukemia. It is new chemical entity, administered through oral route. It acts by targeting STAT3, and beta-catenin.
It was also under development for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Agastiya Biotech overview
Agastiya Biotech is a new medication development business focused on bringing to market unique pharmaceutical products. The company’s cutting-edge approaches have resulted in the development of various unique small compounds with patents for a variety of cancers, including the most difficult leukaemia and pancreatic cancer. The company is headquartered in United States.
For a complete picture of AB-01’s drug-specific PTSR and LoA scores, buy the report here.